◆ NeutralGERN
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire Inc.·
Geron Corporation announced it will release its third quarter 2026 financial results on November 4, 2026, before market open, followed by a conference call at 8:00 a.m. Eastern Time. The hematology-focused biopharmaceutical company is advancing its telomerase inhibitor imetelstat (RYTELO®), which is approved for lower-risk myelodysplastic syndromes in the US and EU, with ongoing Phase 3 trials in myelofibrosis and other blood cancers.
Read Full Article at GlobeNewswire Inc. →